Guggenheim initiated coverage on Tenax Therapeutics with a new price target
$TENX
Biotechnology: Pharmaceutical Preparations
Health Care
Guggenheim initiated coverage of Tenax Therapeutics with a rating of Buy and set a new price target of $16.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/24/2024 | $16.00 | Outperform | Leerink Partners |
| 10/14/2024 | $16.00 | Buy | Guggenheim |
| 9/30/2024 | Outperform | William Blair |